Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Novel Database Unifies the Knowledge of 100 Years of Drug Research

Published: Friday, November 09, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
More than 5000 scientific publications on clinical trials in humans and preclinical animal trials concerning the bioavailability of drugs have been evaluated.

PharmaInformatic has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of new drugs.

Several factors affect the oral bioavailability of drugs. For the first time, these can now be analyzed in detail, thanks to a new resource.

The new resource, called PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability) unifies the results and experiences of the last hundred years of drug research.

The development of the knowledge base began in 2005. Since then the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database.

Each of the 8296 records contains the chemical structure of the investigated drug and up to 17 additional fields, which describe in detail the experimental conditions of the trials (gender, age, health status and number of subjects, genetic differences, the species examined, route of administration, additional medication, method of measurement, drug formulation and further descriptions of the studies).

The knowledge base is a fundamental tool to develop computer models, which can predict the oral bioavailability of new drugs in humans, before clinical trials have to be conducted.

This increases the prospects of new drugs and enhances the safety of clinical trials in humans.

Dr Wolfgang Boomgaarden, founder and CEO of PharmaInformatic, says, 'Our research is a huge step forward in the area of drug development and will improve the efficiency of clinical trials in humans. Fundamental new findings and conclusions can be derived from the knowledge base which will impact future drug discovery and development.'

Oral bioavailability is one of the most important properties of a drug.

If a new drug candidate has low or no oral bioavailability, further drug development will be stopped, because the candidate cannot be absorbed in the body.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Friday, September 12, 2014
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos